The molecular diagnostics business of Abbott (Abbott Park, Ill.) has entered a collaboration with Genentech, Roche, and OSI Pharmaceuticals to develop a molecular test that will assess the clinical benefit of erlotinib (Tarceva), an orally-administered drug that is used to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

April 2008 - Table of Contents

DTTR April 2008 (full PDF issue)

JAMA Study Sends Chill Through IVD Market

Immucor Bets on Blood Genotyping

Third Wave Sees Clinical Revenue Grow 25% in '07

NEJM Study Probes Pharmacogenomics of Warfarin Metabolism

PerkinElmer Acquires Pediatrix’s Newborn Screening Lab

New Bioimaging System Promises Improved HER2 Testing

Ikonisys Boosts Automated FISH Platform with New Reference Lab

Quidel RSV Test Gets CLIA Waiver

Abbott to Co-Develop Pharmacogenomic Test for Lung Cancer Drug

Quest Diagnostics Signs Onto Google Health EHR

ACLA Presses SACGHS for Clarification on Genetic Testing Oversight

Beckman Coulter Launches High-Volume Testing System

IVD Stocks Fall 7%; Inverness Plummets 33%

Lung Cancer-Focused Allegro Diagnostics Raises $4 Million